YSCH 01
Alternative Names: Recombinant L-IFN adenovirus - Shanghai Yuansong Biotechnology; YSCH-01Latest Information Update: 13 Jul 2023
At a glance
- Originator Shanghai Yuansong Biotechnology
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Interferon stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Jun 2023 Phase-0 for Solid tumours (Recurrent, Second-line therapy or greater, Metastatic disease) in China (Intratumoural) (NCT05914935)
- 12 Jun 2023 Binhai Hospital of Fujian Medical University incollabration with Shanghai Yuansong Biotechnology plans a early phase I trial for Glioblastoma (Recurrent) (intracapsular) (injection) (NCT05914935)
- 30 Nov 2021 Phase-I clinical trials in Solid tumours (Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in China (Intratumoural) (NCT05180851)